XORTX Therapeutics Inc.
XRTX.V
TSX
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -42.97% | -4.87% | -18.58% | 4.23% | 5.50% |
| Depreciation & Amortization | -16.36% | -19.00% | 6.97% | 56.97% | 3.13% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -26.19% | 27.68% | -32.68% | -45.32% | -37.26% |
| Operating Income | 26.19% | -27.68% | 32.68% | 45.32% | 37.26% |
| Income Before Tax | -521.93% | 76.86% | -95.46% | 55.98% | 110.05% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -521.93% | 76.86% | -95.46% | 55.98% | 110.05% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -521.93% | 76.86% | -95.46% | 55.98% | 110.05% |
| EBIT | 26.19% | -27.68% | 32.68% | 45.32% | 37.26% |
| EBITDA | 24.44% | -33.25% | -21.95% | 45.42% | 38.16% |
| EPS Basic | -423.38% | 84.95% | -97.23% | 69.69% | 106.92% |
| Normalized Basic EPS | -423.50% | 84.96% | -97.23% | 69.68% | 106.92% |
| EPS Diluted | -424.23% | 84.71% | -97.24% | 69.82% | 106.89% |
| Normalized Diluted EPS | -423.50% | 84.96% | -97.23% | 69.68% | 106.92% |
| Average Basic Shares Outstanding | 30.47% | 53.83% | 63.88% | 45.27% | 45.27% |
| Average Diluted Shares Outstanding | 30.47% | 53.83% | 63.88% | 45.27% | 45.27% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |